靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段早期临床1期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
在研适应症- |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1 Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers and in APOE4 Carriers
Phase 1A SAD: Five or more cohorts of 8 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo. The first 4 cohorts will be male only. The last cohort will be repeated with the max safe dose of the previous cohorts in healthy elderly subjects (male and female of non childbearing potential, > 50years)
Phase 1B MAD: Two or more cohorts of 8 male and female HVs will receive multiple (4) IV bolus injections of study drug or placebo every 72 hours.
100 项与 Artery Therapeutics, Inc. 相关的临床结果
0 项与 Artery Therapeutics, Inc. 相关的专利(医药)
100 项与 Artery Therapeutics, Inc. 相关的药物交易
100 项与 Artery Therapeutics, Inc. 相关的转化医学